FindTrial
Sign In

ABT-267

DRUG8 trials

Sponsors

Abbott, AbbVie (prior sponsor, Abbott)

Conditions

Chronic Hepatitis CChronic Hepatitis C InfectionHCV InfectionHepatitis CHepatitis C (HCV)Hepatitis C Genotype 1Hepatitis C VirusHepatitis C Virus (HCV) Infection

Phase 1

Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
CompletedNCT01181427
AbbottHCV Infection
Start: 2010-08-31End: 2012-01-31Updated: 2012-01-24

Phase 2

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
CompletedNCT01314261
AbbVie (prior sponsor, Abbott)Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
Start: 2011-03-31End: 2013-02-28Updated: 2018-07-02
A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
CompletedNCT01458535
AbbVie (prior sponsor, Abbott)Hepatitis C Virus
Start: 2011-09-30End: 2013-05-31Updated: 2016-07-11
ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
CompletedNCT01464827
AbbVie (prior sponsor, Abbott)Chronic Hepatitis C, Hepatitis C Genotype 1, Hepatitis C (HCV)
Start: 2011-10-31End: 2013-09-30Updated: 2015-04-22
Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects
CompletedNCT01563536
AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection
Start: 2012-02-29End: 2013-06-30Updated: 2018-07-02
A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study
CompletedNCT01609933
AbbVie (prior sponsor, Abbott)Chronic Hepatitis C
Start: 2012-12-18End: 2017-05-03Updated: 2018-06-19
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
CompletedNCT01685203
AbbVie (prior sponsor, Abbott)Hepatitis C, Chronic
Start: 2012-08-31End: 2015-02-28Updated: 2021-07-30

Phase 3

A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
CompletedNCT01773070
AbbVie (prior sponsor, Abbott)Hepatitis C
Start: 2013-06-30End: 2016-10-31Updated: 2017-12-06

Related Papers

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection.
2019-02-13
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
2015-07-1166 citations
Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
Antimicrobial Agents and Chemotherapy2015-06-2395 citations
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
2015-03-31189 citations
<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A
Antimicrobial Agents and Chemotherapy2014-12-02130 citations
Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
New England Journal of Medicine2014-01-15256 citations